Our breakthrough, proprietary technology platform engineered to enhance drug absorption
End-to-end, in-house control of formulation, development, and manufacturing capabilities
Our proprietary cannabinoid composition for the management of pain and inflammation
Partnering with the world’s leading research institutions and doctors to support FDA-authorized investigator-initiated clinical trials
Learn more about cannabidiol from the medical community and regulators
We are modernizing the way medicines are taken
Experts in drug development and delivery, manufacturing, and commercialization
Recent media coverage regarding Orcosa
Company news and announcements
Ewing, NJ – August 1, 2022 – Orcosa Inc. (“Orcosa” or the “Company”), a life sciences company modernizing the way medicines are taken through its next generation drug delivery technology – the Rapid Infusion Technology (RITe™) Platform – congratulated Principal Investigator Michael J. Alaia, M.D. of NYU Langone, and his co-authors on the publication of the positive results from their Phase 1/2 clinical trial utilizing ORAVEXX™ in the American Journal of Sports Medicine. The paper, “Buccally Absorbed Cannabidiol Shows Significantly Superior Pain Control and Improved Satisfaction Immediately After Arthroscopic Rotator Cuff Repair: A Placebo-Controlled, Double-Blinded, Randomized Trial” can be accessed on The American Journal of Sports Medicine’s website, here.
The findings, which were originally presented by Dr. Alaia at the Annual Meeting of the American Academy of Orthopaedic Surgeons, demonstrated that cannabidiol (CBD) administered utilizing the RITe™ Platform effectively reduces pain after shoulder surgery with no safety concerns. Highlights of the results include:
“Orcosa is proud to support Michael and his fellow researchers on the publication of their Phase 1/2 clinical trial results in the prestigious peer-reviewed American Journal of Sports Medicine,” said Orcosa President, Bryan Ridall. “The positive results of this trial are the first step in demonstrating how the technology behind the RITe platform can be harnessed to deliver safe, effective treatments to patients.”
Orcosa is the inventor, developer, and exclusive owner of the RITe™ Platform – a fast acting, easy-to-take tablet engineered to enhance drug absorption. The tablet is designed to rapidly infuse an active ingredient through the tissue in the mouth and enable therapeutic effects quickly and efficiently. Based on the unique manner of administration, RITe™ tablets have the ability to act faster and provide enhanced bioavailability over current formulations while reducing the potential for unwanted side effects for certain compounds. All RITe™ products are manufactured at the Company’s state-of-the-art cGMP-compliant facility in New Jersey.
Co-authors of the publication include Eoghan T. Hurley, Kinjal Vasavada, Danielle H. Markus, Briana Britton, Guillem Gonzalez-Lomas, M.D., Andrew S. Rokito, M.D., Laith M. Jazrawi, M.D., from NYU Langone Health, and Kevin Kaplan, M.D., of Baptist Health in Jacksonville, Florida.
About ORAVEXX™
ORAVEXX™ is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. Historically, research on the effects of CBD has been limited by a variety of issues including inaccurate dosing, low bioavailability, difficult administration, and a lack of GMP-manufactured products with matching placebos with which to conduct clinical research. ORAVEXX™ is being developed to address these issues associated with unreliable and inefficient orally delivered CBD and provide researchers the opportunity to evaluate CBD more accurately in clinical trials.
About Orcosa Inc.
Orcosa Inc. is a life sciences company modernizing the way medicines are taken and improving patient outcomes through its proprietary therapeutic delivery technology, the Rapid Infusion Technology (RITe™) Platform. Orcosa is the inventor, developer and exclusive owner of the RITe™ Platform, a fast acting, easy-to-take tablet engineered to enhance drug absorption. Orcosa’s lead program, ORAVEXX™, is a non-addictive proprietary cannabidiol composition that utilizes the RITe™ Platform to treat pain and has the potential to provide a safe, alternative treatment option to opioids and NSAIDs. The company is currently supporting FDA-authorized clinical trials at leading American research institutions to evaluate the safety and effectiveness of ORAVEXX™ for pain management. For more information on Orcosa, please visit https://www.orcosa.com/.
Forward-Looking Statements
Certain statements made herein constitute “forward-looking statements”. These forward-looking statements include, but are not limited to, the development of ORAVEXX™ and the RITe™ Platform. These statements are based on the current expectations of Orcosa and are not predictions of actual performance. Such forward-looking statements involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Orcosa to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.
Media Contact:
FGS GlobalDevin Brodadevin.broda@fgsglobal.com212-687-8080
Investor Contact:
IR@orcosa.com